1 SUPPORTING THE GROWTH OF LIFE SCIENCES STARTUP COMPANIES BIOVISION 2013 MARCH LYON-FRANCE Co-organized with
2 EDITO Dear Delegate, We all observe a sea change in the biopharmaceutical industry due a shifting health care landscape, expiring patents and generic competition, pricing pressures, heightened regulatory scrutiny and a tough global economy. As a result, funding for life science companies has become ever harder to come by, putting the engine of innovation at risk. Our companies are asked to do more with less capital, and demonstrate outcomes, the earlier the better. The whole industry now finds itself facing this new normal, but among all those worries there is reason for guarded optimism as we take a pause to re-think our current and test new business models in order for our companies to survive and succeed. Historically, the life science industry, comprising Academia, Biotech & Pharma, had been split into separate camps, each focused on building value and maintaining control across the entire value chain. But drug R&D and commercialization has become far too complex for any one company to be good at all of those disparate activities. The obvious solutions are partnership structures in which early innovators get rewarded for, and maintain control of higher-risk stages and where Pharma partners provide development/commercial expertise. Often it is not easy for Pharma as well as Biotech companies to cede authority over those areas in which they aren t competitive and many different structures are tried to address each other s comfort level. Our new partnership models also extend beyond the traditional Pharma Biotech alliances, venture capital investors now work very closely with all stakeholders, including forming direct alliances with Pharma, and thus catalyze successful collaborations. And partnerships don t always have to happen at a competitive level; pre-competitive collaborations can yield tremendous benefits and cost savings for all stakeholders. We see many creative business models being explored and for sure these are only the beginnings. In the end, once we found a new equilibrium, I am very confident that we will we see an industry emerging whose productivity is commensurate with its investment, an industry best prepared to harness the remarkable pace of biomedical discovery for the ultimate benefit of patients. The BIOVISION selection committee had the pleasure to select some of the best European biotech companies and put them on display during this conference. Hence, please join me in welcoming the freshman class of companies, and in wishing for this inaugural version of the BIOVISION Investor Conference 2013 to become a key calendar date in years to come. I want to thank all the participating companies, and of course, my colleagues from the venture capital industry for their diligent work in selecting the best of the crop. Roman Fleck, Index Ventures Chairman of the Selection Committee
3 table of contents programme 5 the selection committee 9 presenting companies 25 partners & sponsors 65 acknowledgments 69
4 WELCOME TO BIOVISION INVESTOR CONFERENCE Welcome to the 1 st edition of BIOVISION INVESTOR CONFERENCE, held on March , at the Cité Internationale of Lyon, France, in conjunction with the BIOVISION World Life Sciences Forum. This event, organised in a very unique and original format in Europe, pairs the most promising lifesciences start-up companies with representatives from leading cross-border venture capital, advisors and global corporate firms. This is the first time that both best young & upcoming start-ups and venture backed startups will present in front of the same audience. Biovision is also delighted to work with Lyonbiopole, world-class cluster in Rhône-Alpes, France, dedicated to the fight against infectious diseases and cancers, as well as with France Biotech, French organization dedicated to promote biotech and med tech businesses in France and EuropaBio, the European association for bio-industries. BIOVISION INVESTOR CONFERENCE promotes personal interactions between participants based on an intensive program that places a priority on networking with high-level decision makers, companies and investors. The event features: Presentations from a limited number of companies selected in advance by a panel consisting of more than thirty international investors active in Europe A schedule of seminars and workshops, focusing on the issues of finance for innovation and access to the market in Europe, moderated by high-level experts A dedicated space designed and equipped for one-on-one meetings scheduled in advance The BIOVISION INVESTOR CONFERENCE Selection Committee, held on March 1 st, selected 37 companies to showcase during the two-day event. The prestigious Selection Committee, representing nearly 10 billion under management, is chaired by Roman Fleck, Index Ventures and is coordinated by Jean-Marc Soustre, Humaneye Invest. In total, approximately 280 company evaluations were performed. The selection reflects a great diversity (11 countries), all activity sectors included: biopharma, medtech and healthcare services. The total amount of funds sought by these 37 companies represents more than 330 million, reflecting the dynamism of the life sciences sector in Europe. Applications included companies based in the United States and Australia and looking to relocate to Europe. On behalf of the organizers, we wish you all a highly successful and productive conference.
5 p r o g r a m m e
6 6 biovision investor conference p r o g r a m m e Monday, March 25, :30 to 10:00 Building a sustainable environment for innovation in Europe Moderated by Paul Seabright - Institute for Advanced Study, Toulouse School of Economics Room Saint Clair 3 11:30 to 12:45 WELCOME PLENARY SESSION: New partnership and investment models for innovation Introduced by Chris Viehbacher - Sanofi Moderated by Albertina Torsoli - Bloomberg News Auditorium Pasteur 02:00 to 03:30 Enabling technology for BioManufacturing challenges & opportunities by 2020 Moderated by JF Hamel MIT / Board member Accinov Room Saint Clair 3 Company Presentations Neurotune Mindseed Labs Dorphan Reflexion Medical PrestoDiag Miracor Medical Room Saint Clair 1 03:30 to 05:30 05:30 to 05:45 Company Presentations Mosaic Biomedicals Ecrins Therapeutics Epitherapeutics Innavirvax Biosourcing DNA Therapeutics Corporate Pitch Johnson & Johnson Room Saint Clair 1 Room Saint Clair 1 1:1 MEETINGS - Room Saint Clair 4&5 05:45 to 07:15 H2020 New investment tools Moderated by Jean-David Malo European Commission Room Saint Clair 2 H2020 New Biotech Opportunities Moderated by Jürg Zürcher Ernst & Young AG Room Saint Clair 3 Investor Conference Evening Salle de la Corbeille - Lyon Chamber of Commerce and Industry
7 biovision investor conference 7 p r o g r a m m e tuesday, March 26, :00 to 09:00 Innovation Strategy & Corporate pitches Mérieux Développement, Sanofi, GSK, Medtronic Moderated by Olivier Exertier - ALGOE Room Saint Clair 3 Company Presentations 09:00 to 10:30 10:45 to 12:30 Company Presentations Xeltis Pixium Vision Presbeasy Abionic Eveon Glysure Picoseq Room Saint Clair 1 VitamFero Enterome Eydo Pharma XL-protein BioAtrix Cytoo Company Presentations Trophos Anergis GenKyoTex Bone Therapeutics TxCell Genticel Probiodrug Room Saint Clair 1 Room Saint Clair 2 1:1 MEETINGS - Room Saint Clair 4&5 01:30 to 03:00 Company Presentations DigitalMediaLab AlzProtect Glyconova GMP Orphan GeNeuro Room Saint Clair 1 03:30 to 04:30 CLOSING PLENARY SESSION: European Commission Horizon 2020: Securing Europe s global competitiveness Moderated by Olivier Raynaud - World Economic Forum Auditorium Lumière
9 the selection c o m m i t t e e
10 the selection c o m m i t t e e index Renee Aguiar-Lucander Omega Funds UK 11 Claus Andersson Sunstone Capital DK 11 Muriel Bekto MÖLNLYCKE HEALTHCARE CH 11 Jasper Bos Merck Serono Ventures CH 12 Diego Braguglia VI Partners AG CH 12 Ivica Cerina NGN Capital DE 12 Aris Constandinides NBGI UK 13 Isabelle de Cremoux Seventure FR 13 Angelo De Rosa Medtronic Europe CH 13 Maciek Drozdz Entrepreneurs Fund Management LLP GB 14 Roman Fleck Index Ventures CH 14 Alexandra Goll TVM Capital DE 14 Marie-Laure Guarrigues CDC entreprises FR 15 Lukas Guenther Wellington Partners Venture Capital GmbH DE 15 Tim Haines Abingworth UK 15 Celia Hart CEA Investissements FR 16 Gérard Hascoet MDStart FR 16 Alain Huriez Advent Venture Partners US/UK 16 Marcel Kloosterman DSM Venturing NL 17 Hans A. KÜpper Global Life Sciences Ventures DE 17 Franck Lescure Auriga Partners FR 17 Jesus Martin-Garcia Eclosion CH 18 Joey Mason Delta Partners IE 18 François Miceli Sofimac FR 19 Daniel O'Mahony Seroba Kernel IE 19 Antoine Papiernik Sofinnova Partners FR 20 Maurizio PetitBon Kreos Capital UK 20 Thom Rasche Earlybird DE 20 Mark Redshaw Evonik Corporate Venturing DE 21 Manus Rogan Fountain Healthcare Partners IE 21 Sven Rohmann Burrill & Company US/CH 21 Christina Takke Forbion Capital Partners NL 22 Davide Turco Atlante Ventures IT 22 François Valencony Merieux Developpement FR 23 Ilka Wicke Boehringer Ingelheim Venture Fund DE 23 Mark Wilson GlaxoSmithKline UK 23
11 biovision investor conference 11 Renee Aguiar-Lucander, Partner Renee Aguiar-Lucander joined Omega Funds after serving as a Partner in the venture capital group of 3i Group Plc in London where she since 2005 was responsible for managing their publicly quoted assets and the European legacy healthcare portfolio. In addition, Renee structured and executed several secondary sale processes whilst at 3i. Prior to joining 3i she was a Managing Director in Investment Banking at Lehman Brothers, with a focus on Business Media & Internet. Renee has over 12 years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private/public capital for growth companies in both Europe and the US. Prior to Investment Banking, Renee worked for 5 years in European sales & marketing for a financial services focused software business. Renee has a BA in finance from Stockholm School of Economics and a MBA from INSEAD. She has significant board experience from both private and public board work and is presently a board member of Sophion Bioscience A/S, NsGene A/S, ImpactRx Inc and Newron Pharmaceuticals SpA. Claus Andersson, Partner Claus Andersson is a partner in the Life Science group and has been with the team since it was established. Claus focuses on medical technology, diagnostics and therapeutics investments and is actively involved in maintaining our strong network to universities and research centers. Claus has extensive experience in strategy execution and technology development from various parts of the Life Science ecosystem: both as an entrepreneur, venture capitalist, scientist, and corporate manager. Claus holds a Master s degree in Civil Chemical Engineering from the Technical University of Denmark (DTU) and a PhD in Mathematical Statistics from the University of Copenhagen and the Humboldt University in Berlin. Outside working hours, Claus interests span from skiing, running to multivariate statistical modeling at the University of Copenhagen a mix providing several sources of recreational activities. Muriel Bekto, Country Manager Surgical Division at Molnlycke Health Care Switzerland 9 years in sales and marketing management in the medical devices sector. 8 years experience in marketing and consulting in the IT industry. Strong international exposure including Western and Eastern Europe, Asia Pacific and Middle East. Specialties: Sales Management People management and talent development marketing - Strategic planning, new product development and introduction, brand management, e-marketing, KOL management. Consulting in supply chain optimization software solutions Project management with experience leading cross-functional teams
12 12 biovision investor conference Jasper Bos, Director Merck Serono Ventures at Merck Serono Dr. Jasper M. Bos is a Director - MS Ventures at Merck Serono S.A., Investment Arm, which he joined in March, Previously, he served as Investment Manager at African Health Systems Management and IFHA. Dr. Bos was instrumental in the structuring and capital raise of the Fund and negotiated and managed investments in Nigeria and other African countries in the healthcare and financial sector. Prior to that, he worked as Health Economics and Strategy Manager at the Netherlands Vaccine Institute. Dr. Bos is a visiting scholar at the University of Groningen, and published over 30 articles on health economics. He holds a Ph.D. in Pharmacy from the University of Groningen, the Netherlands. Jasper is a Board Member of Galecto Biotech, EpiTherapeutics ApS and an Observer to the Board of VAXIMM. Diego Braguglia, General Partner Diego joined VI Partners in January 2003 as a partner focusing on life-science and biotech investments. He brings over 10 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry into the VC industry Diego has held various managerial positions in the pharmaceuticals and medical devices sectors, as well as in biotech start ups in Europe and the US. Diego holds an M. Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne. He is fluent in English, French Italian and German. Diego carries the prime responsibility for the following portfolio companies: Cequr, Covalys, Edimer, Endosense and Novashunt. Ivica Cerina, Partner Dr. Cerina is a Partner of NGN Capital. Ivica Cerina, Ph.D. joined NGN Capital in 2005 from DyoDelta Biosciences Ltd. where he was VP Venture Financing & Business Development. Prior to that, he gained 6 years of venture capital experience at TVM - a leading German-U.S. venture firm with over 1.2B under management - where he was responsible for deal sourcing, due diligence, deal support and business development. At TVM he worked with the partners on existing portfolio companies and new transactions (e.g. Addex, Jerini, SelectX, Direvo) and established a strong international network with leading venture firms, investment banks, biotech & pharma companies. Prior to TVM, Dr. Cerina worked as a consultant advising startups and small and mid-size entities on financing and business strategy. Dr. Cerina studied Biochemistry at the J.W.Goethe University in Frankfurt and performed his doctorate thesis at the Hemostasis Research Unit of the Max-Planck-Institute for Physiological & Clinical Research in Bad Nauheim. Dr. Cerina currently serves on the Board of Directors of NaniRx Therapeutics and holds an observer seat on the board of Vivaldi Biosciences.
13 biovision investor conference 13 Aris Constantinides, Founder and Investment Director Aris is the founder and Investment Director of NBGI Ventures, responsible for its overall strategy and management, and leads its presence in the medical technology sector. Aris established NBGI Ventures in 2001, following five years in venture capital with Deutsche Bank s venture capital team and CSFB s Cabot Square Capital fund. He started his career at Bankers Trust as a derivatives specialist. Aris holds a B.Eng from Imperial College and a SM from MIT in Mechanical Engineering and an MBA from INSEAD. Isabelle de Cremoux, CEO/Managing Partner Isabelle brings 21 years of international experience in life sciences business development and finance. Isabelle started her career in 91 at Arthur Andersen Detroit, US then at Pfizer France and Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development. Since 98, she was Associate Director of Business Development at Fournier and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July Angelo DE ROSA, Head of Strategy & Business Development Angelo De Rosa is responsible for Strategy and Business Development at Medtronic for Europe, Middle East, Africa and Canada (EMEAC). He brings over 17 years of international leadership experience in the medical device business, covering General Management, Business Development, Sales and Marketing, Clinical responsibilities in diversified geographic areas. He is also an entrepreneur, founder of NayaMed International and passionate for disruptive business models in healthcare. Member of the International Grants Committee for the Medtronic Foundation. Active speaker in the MedTech area at European level. Angelo holds a Biomedical Engineer Degree from the University of Pisa, MBA diploma from Politecnico di Milano, Italy. Continuous education from IMD in Lausanne and Wharton Business School, Pennsylvania.
14 14 biovision investor conference Maciek Drozdz, Investment Manager Maciek is an Investment Manager at Entrepreneurs Fund. Before joining EF he was an analyst at Atlas Venture in Munich and an Investment Director at MCI Bioventures in Poland. Maciek holds an MSc in molecular biology from A. Mickiewicz University, and a PhD from Zentrum für Molekulare Biologie in Heidelberg. He also has an MBA from Said Business School in Oxford. Roman Fleck, Principal Roman joined the Life Science team at Index Ventures in 2006 and he is Principal based in the Geneva office.prior to joining Index Ventures, he worked for seven years at Boehringer Ingelheim Pharmaceuticals. Roman received his Ph.D. in organic chemistry from the Massachusetts Institute of Technology (MIT) where he performed research on catalytic antibodies. In addition, he obtained an MBA from New York University s Stern School of Business where he continues to serve as a mentor for aspiring entrepreneurs. Currently, he represents Index Ventures on the boards of GlycoVaxyn, Novocure and Diartis, while remaining closely involved with Versartis, Funxional Therapeutics and Normoxys. Alexandra Goll, General Partner Dr. Alexandra Goll, who joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments. She initiated TVM Capital s lead investment in Actelion Ltd (Allschwil, Switzerland) and led the firm s successful investments in Idenix Pharmaceuticals, Inc. sold to Novartis, and Pharmasset Inc. which was sold to Gilead Sciences TVM Capital acted as a lead investor in both cases. She also initiated and managed the investment in EUSA Pharma Ltd., recently sold to Jazz Pharmaceuticals Inc. Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria) and Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI). She also represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland), MediGene AG (Martinsried), Newron Pharmaceuticals SpA, (Bresso, Italy) and Wilex AG (Munich, Germany). Prior to her affiliation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical development and managing commercialization strategies of products such as Neupogen (under an agreement with Amgen), Hivid, Cymevene and Valcyte. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine.
15 biovision investor conference 15 Marie-Laure Garrigues, Investment Director Marie-Laure Garrigues is a Director of Investments at CDC Entreprises since 2008, and a member of the management team of the Innobio fund since Before joining the VC industry, she was the Microbiology Division Manager at Bio-Rad Laboratories, a California diagnostics company, after moving from Sanofi Diagnostics Pasteur, where she held successive management positions. During her career, she has directed international teams in a variety of programs, including R&D, marketing, and operations. She specialized in microbiology as a research assistant at the Hospital Necker and the Pasteur Institute, before joining the life science industry. Marie-Laure Garrigues is a pharmacist, former hospital internist in Medical Biology in Paris, and holds a DEA from the Faculty of Pharmacy of the University of Paris V. Lukas GUENTHER, Investment Director With an international background in clinical medicine and economics, Lukas joined the Wellington Life Science investment team in Prior to joining Wellington, Lukas had worked for six years as a surgeon and researcher specializing in organ and cell transplantation at the department of surgery at the Universities of Heidelberg and Freiburg. From 2000 to 2002, Lukas was a post-doctoral scientist at Harvard University in Boston, where he conducted research in the fields of immunology and protective genes. In 2003/2004 Lukas completed a fellowship in clinical islet transplantation at the University of Minnesota in Minneapolis, participating in NIH multicenter trials. Lukas studied Medical Sciences in Berlin and Cape Town. He holds a summa cum laude doctorate in Medicine from the Humboldt University Berlin and a Global OneMBA degree from RSM Erasmus University, Rotterdam. Tim HAINES, Partner Tim Haines has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Pharmaceuticals, Fovea, Kspine, Lombard Medical, Pixium Vision, PowderMed, Stanmore Implants and XCounter. Tim has a BSc from Exeter University and an MBA from INSEAD. At Abingworth, he identifies and creates new businesses and provides support for portfolio companies.
16 16 biovision investor conference Celia HART, Investment Director Celia has 15 years experience in the chemical and biotechnology sector. She did her PhD in protein engineering and metabolic engineering at Oxford University (UK) in a laboratory that worked closely with Industry (GSK, DSM). Celia then worked in the UK Biotechnology industry at Cambridge Antibody Technology (now Medimmune) where she was the Head of Lead Optimisation and led the R&D development of several therapeutic antibodies. Since then she has been assessing new business opportunities built on strong science at leading institutions (ESRF, CEA). She joined CEA Investissement (France) in 2005 as an investor and is responsible for the life sciences sector. She serves on the Board of several companies including Cytoo, Fermentalg and Neorphys. Celia holds a degree in Chemistry from the University of Geneva, a PhD from the University of Oxford (UK) and an MBA from Grenoble Ecole de Management (France). Gérard Hascoët, Chairman of the Board Gérard Hascoët is Chairman of the Board of MD Start (Germany& Switzerland), Chairman of the Board of SpineVision (France), Chairman and CEO of CorWave (France), Director of the Board of APD (France), Director of the Board of Dupont Medical (France). He is also Venture Partner for the French based Venture Capital firm Sofinnova Partners. Prior to becoming active in MedTech investment, Gérard was Serial entrepreneur in the MedTech. In the eighties he founded Technomed International, a company developing non invasive therapeutic technologies dedicated to Urology. He grew the company to its IPO in 1989 with 50 Million sales. In the nineties he founded 2 companies: IMMI developing Neurosurgery Image guided Robotic systems and SOMETEC developing non invasive Hemodynamic monitoring dedicated to Anesthesiology and Intensive Care. Both companies were acquired by US based companies listed on the NASDAQ (ISS and ARROW International). Most recently as CEO he turned around SpineVision a developer and Manufacturer of Spinal Implants Prior to becoming an entrepreneur, Gérard began his career within the French Thomson Group, where he held during 15 years various management positions in the MedTech branch. Gérard is an engineer graduated from E.C.E Paris. Alain Huriez, Venture Partner Alain joined Advent in 2012 bringing 22 years of experience in management, drug development and financing in the life sciences sector, including CEO of TcLand Expression and Neovacs, Associate Partner at Truffle Capital and Vice President at Quintiles. Alain is a medical doctor and holds an MBA and a Masters of Pharmaco-Economics from Paris La Sorbonne University. Prior to joining the industry, he was head of the emergency room in a large teaching hospital and practiced as a General Practitioner for two years. Alain has been responsible for several initiatives in Europe within the areas of personalized medicine, biomarkers and high value diagnostics through his work as chairman of EPEMED, the European Personalised Medicine Association. As an entrepreneur, and in addition to TcLand Expression, he also co-founded three French biotechnology companies.
17 biovision investor conference 17 Marcel KLOOSTERMAN, Investment manager Dr Marcel Kloosterman has worked for DSM since 1985 in various functions. Currently Marcel is investment manager for 2 DSM-related Venture Capital activities, being DSM Venturing (DSM s corporate investment group; fund size 200 Mln) and Limburg Ventures (a fund co-founded by DSM with regional focus), both residing at the DSM Innovation Center in NL. Targeting break-through start-up companies that are looking for equity financing by DSM, and could benefit from DSM s strongholds (IP, M&S channels, management, production et al.) in the areas of Lifesciences (pharma, nutrition, feed, personal care), Performance Materials(resins, coatings, (bio)-polymers, strong fibers, engineering plastics) or DSM s Emerging Business Areas(eg biomedical materials, white biotech). Holding board seats in several European startups, and acting as advisory board member in several panels. Sectors of Personal Expertise: life sciences/ energy, clean technology, environment. Hans A. Küpper, Partner Dr. Küpper has a total of 29 years experience in biotechnology with 19 years in the life science industry, where he was involved in activities from research and R&D management to technology assessment and acquisition. In February 1999, Dr. Küpper joined as a Managing Director of GLS I s advisory company, based in Munich, Germany. Since that time he has been advising GLS I and managing GLSV II in all aspects of investments. Dr. Küpper is a board member, or attendee, with a number of portfolio companies, one of which is now listed on the Vienna Stock Exchange and one at NASDAQ. He received his PhD from the University of Heidelberg in 1974 and spent two years as a postdoctoral fellow at MIT in Boston with Nobel Laureate Prof. Khorana. After another four years at Heidelberg University he joined Biogen in Geneva, one of the pioneering biotech companies, in There he held various R&D and management positions with increasing responsibilities and was Assistant Research Director from 1982 to In 1985, he joined Behringwerke AG to build up and head their Molecular Biology department. Later he became head of R&D and member of the board of their Immunology/Oncology business unit. His major research focus was on gene regulation and vaccines. Since 1991 he has been increasingly involved in deal negotiations and various aspects of company restructuring such as acquisitions, joint ventures and spin-offs, including the spin-offs of their vaccine unit and diagnostics business. Dr. Küpper, born in 1944, is author of 50 scientific publications and 13 patent applications. He has served as a consultant for the pharmaceutical industry and the European Commission. Franck lescure, Partner Franck joined Auriga Partners in He is responsible for investments in life sciences. He currently serves on the board of directors of several portfolio companies including Cytoo, Erytech, Médian, TcLand and TxCell. In 2003, Franck joined Crédit Lyonnais Private Equity, after 5 years spent at the Commercial and Medical Departments of Air Liquide Santé, the Healthcare subsidiary of Air Liquide. He began his career in Genset, from 1990 to 1995, in Paris and San Diego, working on therapeutic applications of oligonucleotides and the development of a new-generation DNA synthesizer. Franck is an alumnus of the Ecole Normale Supérieure and has a PhD in Molecular Virology. He is also a graduate of the Institut Pasteur and hold a MBA from Collège des Ingénieurs.
18 18 biovision investor conference Jesús Martin-Garcia, Founder and GP Jesús started his career at the World Economic Foundation, and later at McKinsey & Co. focusing on Pharma and Food industries. In 1991 Jesús chose the entrepreneurial path, becoming the co-founder of LeShop, Switzerland s largest and most successful e-commerce company, and investing seed capital and supporting the creation of a number of other start-ups such as Silverwire or VTX. His entrepreneurial drive led to the launch of the Eclosion platform in 2004, to translate breakthrough science into life-altering drugs. This platform is a unique structure, with a public-private partnership that drives projects from the lab to clinical trials, as demonstrated by companies such as GeNeuro and GenKyoTex. These companies that were started as exploratory programs in the incubator are now testing first-in-class drugs in clinical trials. Jesús has a MS in Economics and a Master in Law from University of Geneva, and an MBA from Harvard Business School. He chairs the Board of other Eclosion start-ups such as GeNeuro and ArisGen. Joey MASON, Partner Joey Mason joined Delta Partners in 2003, specialising in Life Science investments. He serves on the boards of Genable Ltd, Glysure Ltd, Miracor Medical Systems GmbH, SpineGuard SA, Accunostics Ltd and Neuravi Ltd. He serves as an observer on the board of QStream, Inc. Having trained as a doctor, Joey spent five years as an investment banker in the Health Care market with Morgan Stanley International and Technomark in London. From 1995 until 1999 he was Director of Corporate Development at Biotrin Holdings plc, an Irish biotechnology company backed by Delta Partners and other VCs. In 2000 he co-founded and managed Eumom Ltd, a marketing services business operating websites for pregnant women in Germany, Ireland, Switzerland and the UK. A medical graduate of Trinity College, Dublin, he is a Fellow of the RSA and serves on the council of the EVCA.
19 biovision investor conference 19 François A. MICELI, Member of the Investment Board & Venture Partner 48 years old, graduated in biology engineering from Paris XII UPEC University then from INSEAD (EE, Corporate Finance) and from IHEDN (Institut des Hautes Etudes de Défense Nationale, promotion Chevalier Bayard). François Miceli has started is carrier in one of the first French public biotechnology company called CLONATEC within OHF Holding group, where he has served as International Product Manager. End of 1990, François has joined the US NASDAQ listed company called IDEXX Laboratories Incorporated where he successively served as Director for Europe in an international business unit, General Manager of the French subsidiary IDEXX France S.A and then Chief Executive Officer of the Italian subsidiary IDEXX Laboratories Italia. During all the time spent with IDEXX, François Miceli was member of the European Managing Committee. Back to France in 1998, François Miceli joined Synbiotics, spin off from MERIAL as Director of European operations before founding LMD Pharma, a biotech start up with the support of several major venture capital funds such as Banexi Ventures, LCF Rothschild, Siparex et Sofimac Partners. From the end of 2003 to February 2011, François MICELI served as Chief Executive Officer of the integrated biopharmaceutical company IMAXIO dedicated to innovative vaccines for infectious diseases and oncology. Since February 2009, François also served as CEO of AXCELL BIOTECHNOLOGIES, the fully owned IMAXIO subsidiary. During this period IMAXIO has received in 2009 the 3rd prize of Deloitte Fast 50 and the 2nd prize of Deloitte Fast 50 in During this period, François Miceli was Managing Director of EDULIS Technology, a private holding for technology asset management, part of the IMAXIO group. Since February 2011, François Miceli is founder and Chief Executive Officer of Zophis sas, a French company dedicated to in-license early stage vaccine projects. He also serves as Senior Investment Partner with SOFIMAC Partners Capital Investment where he is in charge of innovation investments. He is also a member of the economic board of the vaccine cluster LyonBiopôle and member of the industrial council of CLARA (Cancéropôle Auvergne Rhône-Alpes). Until May 2009, François Miceli was Chairman of ERYtech Pharma S.A and he is a former board member of SIMV (Syndicat de l Industrie du Médicament Vétérinaire) and of several biotech companies. Daniel O Mahony, Partner Daniel O Mahony is a Partner at Seroba Kernel Life Sciences Limited, the largest life sciences VC fund in Ireland. He sits on the board of a number of companies including Apica Cardiovascular Ltd and Novate Medical Ltd. Daniel previously worked in a variety of product development, business development, corporate venturing and asset divestment roles at Elan Corporation, Taro Pharmaceuticals and BSM Management Consultancy. In 2005 he established the Technology Transfer Office at the National University of Ireland, Galway. Daniel graduated with a Ph.D. from the National University of Ireland, Cork and holds a business degree in technology management from the Smurfit Business School, University College Dublin. He has held academic appointments in both Ireland and the USA and has published in several scientific journals and is co-inventor on numerous patent families.
20 20 biovision investor conference Antoine Papiernik, Managing partner Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in Antoine has been an initial investor and active board member in public companies like Actelion, Addex, Orexo, NovusPharma (then sold to CTI), Movetis (then sold to Shire) and Stentys, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis). He has also invested in and is a board member of private companies MD Start, CoAxia, EOS, Mainstay and Recor. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. For 2012 and 2011, Antoine has been recognized on the Forbes Midas List of the top dealmakers in life-science and high-tech venture capital. Antoine is one of the only Europeans on the list, and one of the few life-science investors as well. Maurizio PetitBon, General Partner Over the past 30+ years, Mr. PetitBon has built a career as manager, advisor, entrepreneur and investor in a wide variety of high-growth companies. Mr. PetitBon has worked and lived in several European countries and in the US. Mr. PetitBon joined Kreos Capital and in 1998 and for the past 12 years has focused on identifying, assessing and managing continental European and life science transactions as well as participating in the management and execution of Kreos s overall strategy. Thom RASCHE, Partner Thom Rasche joined Earlybird as a Venture Partner in 2003 and was promoted to Partner in Thom has more than 11 years experience as investor. Further, he is a seasoned executive in the medical device and diagnostic sectors with over 25 years of operational experience. Since he joined Earlybird, Thom has been responsible for the medical device portfolio and new investments in this area. He has successfully led various financing rounds in both European and US based companies. He is an observing board member of Hemoteq AG (Aachen, Germany) and is currently on the board of EBS Technologies GmbH (Berlin, Germany), Miracor Medizintechnik GmbH (Vienna, Austria) and Zonare Medical Systems, Inc. (Mountain View, CA). Additionally Thom was a board member of BMEYE B.V. (Amsterdam, Netherlands), which was sold to Edwards Lifescience Corporation in 2012 and an observer at Calypso Medical Technologies Inc, (Seattle, WA) which was sold to Varian Medical Systems Inc. in Before joining Earlybird, Thom was the Managing Director for Ethicon Endo-Surgery, a Johnson & Johnson company and was responsible for growing the company to be the market leader of minimal invasive surgery in Germany. Prior to Ethicon, Thom was the Vice President Europe for Critikon, the inventor of non-invasive automated blood pressure monitoring where he was responsible for the European organization and the European Development Centre in Wales. Thom has also held various senior marketing and sales positions with Johnson & Johnson in Europe and the US. Thom Rasche holds a Degree as Diplom Kaufmann (MBA equivalent) from the University of Applied Sciences in Lüneburg, Germany, specializing in marketing and human resource management.